310 related articles for article (PubMed ID: 16835474)
1. [Capecitabine].
Yamaguchi K; Shimamura T; Tada M
Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
3. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
5. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Twelves C
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
[TBL] [Abstract][Full Text] [Related]
6. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
7. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
9. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
10. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
11. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Hoff PM; Pazdur R; Lassere Y; Carter S; Samid D; Polito D; Abbruzzese JL
J Clin Oncol; 2004 Jun; 22(11):2078-83. PubMed ID: 15169794
[TBL] [Abstract][Full Text] [Related]
13. Role of oral chemotherapy in colorectal cancer.
Donehower RC
Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416
[TBL] [Abstract][Full Text] [Related]
14. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy.
Koukourakis G; Kouloulias V; Zacharias G; Koukourakis M
J BUON; 2010; 15(4):652-9. PubMed ID: 21229625
[TBL] [Abstract][Full Text] [Related]
16. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Iqbal S; Lenz HJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
